To further validate the findings from Figure 6, where pharmacological IFN blockade improved PDA sensitivity, we used siRNA to specifically knock down type I (IFNAR1 and IFNAR2) or type II (IFNGR2) IFN receptors in four PDA cell lines. The gene discussed is IFNAR1; the disease is Patent ductus arteriosus.